Ruben Niesvizky

Ruben Niesvizky

UNVERIFIED PROFILE

Are you Ruben Niesvizky?   Register this Author

Register author
Ruben Niesvizky

Ruben Niesvizky

Publications by authors named "Ruben Niesvizky"

Are you Ruben Niesvizky?   Register this Author

100Publications

3015Reads

39Profile Views

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Sep 29;19(9):570-578.e1. Epub 2019 May 29.

Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.05.017DOI Listing
September 2019

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Clin Lymphoma Myeloma Leuk 2019 Aug 2;19(8):522-530.e1. Epub 2019 May 2.

Department of Clinical Therapeutics, University Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.04.018DOI Listing
August 2019

Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.

Am J Hematol 2019 May 25;94(5):539-545. Epub 2019 Feb 25.

Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25435DOI Listing
May 2019

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Blood 2019 May 28;133(18):1953-1963. Epub 2019 Feb 28.

Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-874396DOI Listing
May 2019

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.

Blood Adv 2019 Feb;3(4):603-611

Division of Hematology/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018028027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391672PMC
February 2019

High-Cutoff Hemodialysis in Myeloma Cast Nephropathy.

JAMA 2017 12;318(21):2085-2086

Division of Hematology and Medical Oncology, Multiple Myeloma Center, Weill Cornell Medical Center, New York Presbyterian Hospital, New York City, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2017.18710DOI Listing
December 2017

Advances in immunotherapy in multiple myeloma.

Curr Opin Oncol 2017 Nov;29(6):460-466

Division of Hematology and Medical Oncology, Multiple Myeloma Center, New York City, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000407DOI Listing
November 2017

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

Biol Blood Marrow Transplant 2017 Jun 8;23(6):930-937. Epub 2017 Mar 8.

Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.03.007DOI Listing
June 2017

Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.

Semin Oncol 2016 Dec 11;43(6):709-711. Epub 2016 Nov 11.

Division of Hematology/Oncology, Weill Cornell Medical Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.11.006DOI Listing
December 2016

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Leuk Lymphoma 2015 12;56(10):2959-61. Epub 2015 May 12.

g John Theurer Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1020801DOI Listing
September 2016

Clinical characteristics of patients with relapsed multiple myeloma.

Cancer Treat Rev 2015 Dec 31;41(10):827-35. Epub 2015 Jul 31.

Department of Hematology, University of Torino, Via Genova 3, 10126 Torino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2015.07.005DOI Listing
December 2015

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

J Clin Oncol 2015 Nov 8;33(33):3921-9. Epub 2015 Jun 8.

Ruben Niesvizky, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Ian W. Flinn, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Robert Rifkin, US Oncology Research/McKesson Specialty Health, The Woodlands, TX; Nashat Gabrail, Gabrail Cancer Center, Canton, OH; Veena Charu, Pacific Cancer Medical Center, Anaheim, CA; Billy Clowney, Santee Hematology/Oncology, Sumter, SC; James Essell, Sarah Cannon Research Institute and Oncology Hematology Care, Cincinnati, OH; Yousuf Gaffar, University of Maryland-St Joseph Medical Center, Towson, MD; Thomas Warr, Clinic Cancer Care, Great Falls, MT; Rachel Neuwirth, Yanyan Zhu, Jennifer Elliott, Dixie-Lee Esseltine, and Liviu Niculescu, Millennium Pharmaceuticals, Cambridge, MA; and James Reeves, Sarah Cannon Research Institute and Florida Cancer Specialists, Fort Myers, FL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/06/08/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.7618
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.7618DOI Listing
November 2015

Pulmonary hypertension complicating multiple myeloma.

Pulm Circ 2015 Sep;5(3):590-7

Division of Cardiology, Weil Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/682430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556512PMC
September 2015

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.

Leuk Lymphoma 2014 Dec 25;55(12):2842-9. Epub 2014 Mar 25.

Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.896005DOI Listing
December 2014

Treatment of multiple myeloma with carfilzomib in patients with renal injury.

Clin Adv Hematol Oncol 2013 ;11(9):605-6

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
October 2014

[Living medicine: the patient, tie and cock].

Authors:
Rubén Niesvizky

Rev Invest Clin 2014 Jan-Feb;66(1):5-6

Weil Cornell University. Medical College.

View Article

Download full-text PDF

Source
July 2014

Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.

Leuk Res 2014 May 13;38(5):517-24. Epub 2014 Mar 13.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital - Cornell Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.02.008DOI Listing
May 2014

IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.

Mod Pathol 2014 Mar 13;27(3):375-81. Epub 2013 Sep 13.

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.159DOI Listing
March 2014

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

J Clin Oncol 2014 Feb 13;32(6):587-600. Epub 2014 Jan 13.

Antonio Palumbo and Alessandra Larocca, University of Torino, Torino; Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Jesus F. San Miguel, University Hospital of Salamanca, Salamanca, Spain; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Ola Landgren, National Cancer Institute, Bethesda, MD; Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic; Hermann Einsele, University of Wurzburg, Wurzburg, Germany; Kenneth C. Anderson and Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Meletios A. Dimopoulos, University of Athens School of Medicine, Athens, Greece; Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia; A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Kazuyuki Shimizu, Aichi Gakuin Hospital, Nagoya, Japan; Sagar Lonial, Emory University, Atlanta, GA; Pieter Sonneveld, Erasmus Medical Centre, Rotterdam, the Netherlands; Brian G.M. Durie, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Philippe Moreau, University Hospital, Nantes, France; and Robert Z. Orlowski, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/6/587.full.pdf
Web Search
https://myeloma.org/pdfs/IMWG_Pub/2014%20JCO-%20Palumbo-%20I
Web Search
http://szpiczak.org/lang/aktualnosci/publikacje/rok_2013/LUD
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.48.7934
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.7934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918540PMC
February 2014

Immunomodulatory agents changing the landscape of multiple myeloma treatment.

Authors:
Ruben Niesvizky

Crit Rev Oncol Hematol 2013 Oct 12;88 Suppl 1:S1-4. Epub 2013 Jun 12.

Department of Medicine, Division of Hematology Oncology, Center of Excellence of Lymphoma and Myeloma, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2012.12.011DOI Listing
October 2013

How lenalidomide is changing the treatment of patients with multiple myeloma.

Crit Rev Oncol Hematol 2013 Oct 28;88 Suppl 1:S23-35. Epub 2013 Jun 28.

Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.05.013DOI Listing
October 2013

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Biol Blood Marrow Transplant 2013 May 20;19(5):831-7. Epub 2013 Feb 20.

Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.02.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985064PMC
May 2013

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.

Blood 2013 Mar 8;121(11):1982-5. Epub 2013 Jan 8.

Division of Hematology and Medical Oncology, Department of Medicine, Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-08-44
Publisher Site
http://dx.doi.org/10.1182/blood-2012-08-448563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596960PMC
March 2013

Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.

Cancer Treat Rev 2012 Dec 18;38(8):1012-9. Epub 2012 May 18.

Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, 80 Vas. Sofias, Athens 11528, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.02.009DOI Listing
December 2012

Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

Leuk Res 2012 Nov;36 Suppl 1:S19-26

Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria, San Giovanni Battista di Torino, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0145-2126(12)70005-XDOI Listing
November 2012

Bortezomib-induced thrombotic thrombocytopaenic purpura.

BMJ Case Rep 2012 Aug 1;2012. Epub 2012 Aug 1.

Department of Medicine, New York Presbyterian-Weill Cornell Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://casereports.bmj.com/cgi/doi/10.1136/bcr-2012-006461
Publisher Site
http://dx.doi.org/10.1136/bcr-2012-006461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544112PMC
August 2012

Novel therapies in monoclonal gammopathies.

Authors:
Rubén Niesvizky

Hematology 2012 Apr;17 Suppl 1:S121-4

Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1179/102453312X13336169156294DOI Listing
April 2012

Necrotizing soft tissue infection in two patients with multiple myeloma.

Surg Infect (Larchmt) 2011 Oct 11;12(5):391-5. Epub 2011 Oct 11.

Department of Surgery, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/sur.2010.087DOI Listing
October 2011

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

Cancer 2011 Jan 22;117(2):336-42. Epub 2010 Sep 22.

Department of Medicine, Division of Hematology Oncology, Center of Excellence of Lymphoma and Myeloma, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010462PMC
January 2011

Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.

Oncology (Williston Park) 2010 Mar;24(3 Suppl 2):14-21

Weill Cornell Medical College, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
March 2010

Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia.

J Natl Compr Canc Netw 2010 Feb;8 Suppl 1:S13-20

Weill Cornell Medical College, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2010.0112DOI Listing
February 2010

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.

J Clin Oncol 2010 Jan 9;28(1):132-5. Epub 2009 Nov 9.

Division of Hematology, Blood/Marrow Transplant and Myeloma Program, 30 N 1900 E, 5C402, University of Utah, Salt Lake City, UT 84132, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.23.0169DOI Listing
January 2010

Outcome of deferred initial therapy in mantle-cell lymphoma.

J Clin Oncol 2009 Mar 2;27(8):1209-13. Epub 2009 Feb 2.

Starr Building Rm 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.6121DOI Listing
March 2009

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.

J Immunol 2009 Feb;182(4):1810-7

Department of Pathology, Weill Medical College of Cornell University, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.0713726DOI Listing
February 2009

Novel agents in myeloma: an exciting saga.

Cancer 2009 Jan;115(2):236-42

Division of Hematology and Medical Oncology, Department of Medicine, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.24040
Publisher Site
http://dx.doi.org/10.1002/cncr.24040DOI Listing
January 2009

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.

Expert Opin Investig Drugs 2009 Jan;18(1):99-104

Weill Medical College of Cornell University, New York Presbyterian Hospital-Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543780802636162DOI Listing
January 2009

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Br J Haematol 2008 Dec 16;143(5):654-60. Epub 2008 Oct 16.

Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital-Cornell Medical Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2008.07374.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626496PMC
December 2008

Aspirin as thromboprophylaxis in myeloma.

Leuk Lymphoma 2008 Aug;49(8):1646-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802199978DOI Listing
August 2008

Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.

J Biol Chem 2008 Jul 23;283(28):19192-200. Epub 2008 Apr 23.

Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M800100200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443646PMC
July 2008

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Biol Blood Marrow Transplant 2008 Jul;14(7):795-8

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2008.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626097PMC
July 2008

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

Cancer 2008 May;112(10):2228-32

Center for Lymphoma and Myeloma, Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23422DOI Listing
May 2008

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.

Semin Hematol 2008 Apr;45(2):126-32

Center for Lymphoma and Myeloma, Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2008.02.007DOI Listing
April 2008

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.

Leuk Lymphoma 2008 Apr;49(4):719-26

Centre for Lymphoma and Myeloma, Division of Haematology/Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190801927387DOI Listing
April 2008

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

Leuk Lymphoma 2008 Mar;49(3):447-50

Division of Hematology - Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701837330DOI Listing
March 2008

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Clin Adv Hematol Oncol 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2

Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA,

View Article

Download full-text PDF

Source
http://myeloma.org/pdfs/2007%20Cl%20Adv%20Hem%20Onc-%20A%20P
Web Search
October 2007

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Br J Haematol 2007 Sep;138(5):640-3

Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital-Cornell Medical Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2141.2007.06698.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2007.06698.xDOI Listing
September 2007